Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 301-307

  Kim, Jong Gwang ^a,b   Ryoo, Baek Yeol ^a   Park, Yeon Hee ^a,c   Kim, Bong Seog ^a,d   Kim, Tae You ^a,e   Im, Young Hyuck ^a,c   Kang, Yoon Koo ^a,f  

^a Korea Cancer Center Hospital   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul Veterans Hospital   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Gastric cancer; Prognostic factor

Indexed keywords

BILIRUBIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; STOMACH ADENOCARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CISPLATIN; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36348957287     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0476-x     Document Type: Article

References (30)

1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29
2. Ries LAG, Eisner MP, Kosary CL (2004) SEER cancer statistics review, 1975-2001, National Cancer Institute, Bethesda
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
5. Glimelius B, Hoffmann K, Haglund U, Nyrén O, Sjödén PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189-190
6. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
7. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893-1898
8. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Ann of Oncol 11:301-306
9. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
10. Tsujitani S, Oka S, Suzuki K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N (2001) Prognostic factors in patients with advanced gastric cancer treated with by noncurative resection: a multivariate analysis. Hepatogastroenterology 48:1504-1508
11. Tas F, Aykan NF, Aydiner A, Uygun K, Basaran M, Camlica H, Topuz E (2000) The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival. Am J Clin Oncol 23:53-57
12. Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, Bodey GP (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2:305-310
13. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, Andre T, Gamelin E, de Gramont A (2003) Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer invest 21:14-20
14. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D (1994) Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30:1263-1269
15. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-Pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395-2403
16. World Health Organization (1979) WHO handbook for reporting results of cancer treatment, WHO Offset Publ., No. 4. World Health Organization, Geneva
17. Gallo A, Cha C (2006) Updates on esophageal and gastric cancers. World J Gastroenterol 2006:3237-3242
18. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404-1413
19. Mitry E, Douillard JY, van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol 15:1013-1017
20. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 23:175-183
21. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994
22. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503-509
23. Kienle P, Koch M (2002) Are "micrometastases" of the peritoneum equivalent to distant metastases? Dis Surg 19:453-458
24. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737-3743
25. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347-354
26. Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S, Seo Y, Fukuda T, Tomoda H (1999) Diffuse bone metastasis with hematologic disorders from gastric cancer : clinicopathological features and prognosis. Oncol Rep 6:601-605
27. Chu KM, Law S, Branicki FJ, Wong J (1998) Extrahepatic biliary obstruction by metastatic gastric carcinoma. J Clin Gastroenterol 27:63-66
28. Baek JH, Kim JG, Jeon SB, Chae YS, Kim DH, Sohn SK, Lee KB, Choi YJ, Shin HJ, Chung JS, Cho GJ, Chung HY, Yu W (2006) Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 94:1407-1411
29. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
30. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Salas MP, Suarez T, Santamaria J (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer. J Clin Oncol 24:4018a